Site icon Impactiviti

Impactiviti Daily 082709

Did you know you can get Impactiviti Daily (Top Pharma News) direct to your Inbox each morning? Just click here to subscribe!


Lots on J&J today – Elimination of the comprehensive care business unit; warnings of allergic reactions to its HIV drug Intelence; FDA finger-wagging for “misleading” advertising of athlete’s foot cream; no further development of once-per-month Risperdal Consta.

Up-and-coming new drugs looking encouraging: eye drug Xibrom QD from Ista, and lupus drug from UCB/Immunomedics.

BMS‘ RA drug Orencia gets an expanded label.


Talent Management. Employee Assessments. We can help. The Impactiviti Partner Network has what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!


The Golden Rule? Or the Gold-in Rule? What’s at the heart of your business? A guest post on the leading healthcare blog KevinMD. AND – Pharma Exec’s listing of the Top 50 Pharma Companies (2008)


Talent. Sometimes these TV shows uncover gems. Check out this guy from X-Factor:


Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Exit mobile version